Subcutaneous Immunoglobulin (SCIG) Market – Opportunities, Share, Growth and Competitive Analysis and Forecast 2029
Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors
How Much Will The Subcutaneous Immunoglobulin (SCIG) Market Be Worth By 2029?
The market for subcutaneous immunoglobulin (SCIG) has seen considerable growth in recent years, and its expansion will continue with the size increasing from $12.72 billion in 2024 to $14.39 billion in 2025. This represents a compound annual growth rate (CAGR) of 13.1%. Various factors have caused this historic growth, including a rise in cases of immunodeficiency disorders, a preference among patients for home-based care, improved therapeutic efficacy, increased awareness and diagnostic rates, and the growth of favorable reimbursement policies.
In the coming years, significant expansion is anticipated in the subcutaneous immunoglobulin (SCIG) market. It’s projected to swell to $23.23 billion by 2029, with a compound annual growth rate (CAGR) of 12.7%. The surge during the estimated period can be linked to the growing incidence of neurological disorders, heightened occurrence of autoimmune diseases, increased awareness and acceptance of immunoglobulin therapy, and extending applications in neurology and dermatology, along with broadened healthcare facilities. Key trends during this projected period include progress in drug delivery systems, an escalated demand for home infusion therapies, advancements in antibody therapy, novel developments in formulations, and innovative forays in SCIG.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp
Which Demand Drivers Are Strengthening The Subcutaneous Immunoglobulin (SCIG) Market?
The surge in secondary immunodeficiency diseases is predicted to fuel the expansion of the subcutaneous immunoglobulin market in the future. Such diseases result in a weakened or compromised immune system owing to factors apart from the immune system itself. These diseases’ prevalence is influenced by various elements such as an aging population, administering immunosuppressive treatments, and exposure to environmental toxins. Subcutaneous immunoglobulin therapy aids the impaired immune system by supplying antibodies, especially in chronic disorders like HIV or autoimmune diseases. It aids in preventing infections and ensuring immunological functionality during treatment. For instance, in October 2023, the UK Health Security Agency, a governmental organization based in the UK, reported 3,805 new HIV diagnoses in England in 2022, showing a 22% increase from the prior year. Consequently, the surge in secondary immunodeficiency diseases prevalence is spurring the expansion of the subcutaneous immunoglobulin market.
How Is The Global Subcutaneous Immunoglobulin (SCIG) Market Broken Down By Segment?
The subcutaneous immunoglobulin (scig) market covered in this report is segmented –
1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM)
2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications
3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses
Subsegments:
1) By Immunoglobulin A (IgA): IgA1, IgA2
2) By Immunoglobulin G (IgG): IgG1, IgG2, IgG3, IgG4
3) By Immunoglobulin M (IgM): Pentameric IgM, Hexameric IgM
Which Trends Are Likely To Redefine Growth Paths In The Subcutaneous Immunoglobulin (SCIG) Market?
Leading firms active in the subcutaneous immunoglobulin market are concentrating on the development of subcutaneous human-klhw. This unique blend contains human immune globulins (Ig) that boost the immune system. The use of subcutaneous human-klhw is primarily for subcutaneous application and has been designed to combat primary immunodeficiency diseases within the human body. For example, in March 2022, Grifols S.A., a pharmaceutical firm based in Spain, introduced XEMBIFY 20% subcutaneous immunoglobulin (SCIG), specially created to address primary immunodeficiency, catering to a substantial medical requirement for individuals with compromised immune systems. XEMBIFY, a ready-to-use formulation, has simplified the treatment procedure, thereby increasing patient ease. As it retains stability at room temperature for a duration of 24 months, there is no need for it to be refrigerated during storage and transit, making it particularly beneficial in numerous healthcare environments.
Who Are The Most Influential Companies In The Subcutaneous Immunoglobulin (SCIG) Market?
Major companies operating in the subcutaneous immunoglobulin (SCIG) market are Pfizer Inc., Johnson & Johnson, Prothena Corporation plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Behring, Lonza Group, Grifols S.A., Octapharma AG, Dr. Reddy’s Laboratories, Intas pharmaceutical Ltd., Emergent BioSolutions Inc., Kedrion Biopharma, LFB group, Biotest AG, Argenx SE, Bio Products Laboratory Ltd., ADMA Biologics Inc., Sino Biological Inc., Bharat Serums and Vaccines Limited (BSV), Kamada Pharmaceuticals, CinnaGen Co., Shire plc
Access The Complete Report Here:
Which Geographic Regions Are Creating Strong Demand In The Subcutaneous Immunoglobulin (SCIG) Market?
North America was the largest region in the subcutaneous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=15935&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
